|Articles|November 20, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
Checkpoint Inhibitors in Cancer Care
Author(s)Jeffrey A. Sosman, MD
Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
In addition to other immunotherapies, Sosman says he is interested in
Articles in this issue
about 12 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersabout 12 years ago
Immunotherapy—An Increasingly Important Role in Oncologyabout 12 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyabout 12 years ago
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhDabout 12 years ago
PD-1 and PD-L1 Antibodies in Lung Cancerabout 12 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadeabout 12 years ago
Nivolumab Plus Ipilimumab in Advanced Melanomaabout 12 years ago
The Outlook for ImmunotherapiesRelated Content
Advertisement
